Shares of Valeant Pharmaceuticals International (NYSE:VRX) advanced to $22.45. The price had gained 0.13% or 0.03 points intraday. The latest trading session witnessed $46.77 million in upticks and $57.62 million in downticks, resulting in net money flow of (-10.85) million. The up/down ratio for the day stood at 0.81. On a weekly scale, the price has seen a change of -7%. From the trading data available, it was disclosed that a block trade of negative money flow worth $(-3.45) million occurred during the day. $4.32 million in uptick and $7.77 million in downtick were the highlight of the block transaction which had an up/down ratio of 0.56.
Valeant Pharmaceuticals International, Inc. has lost 8.7% in the last five trading days and dropped 20.89% in the last 4 weeks. Valeant Pharmaceuticals International, Inc. has dropped 18.31% during the last 3-month period . Year-to-Date the stock performance stands at -78.32%.
Currently the company Insiders own 8.62% of Valeant Pharmaceuticals International shares according to the proxy statements. Institutional Investors own 78.75% of Valeant Pharmaceuticals International shares. . On the companys insider trading activities, The Securities and Exchange Commission has divulged in a Form 4 filing that the CEO of Valeant Pharmaceuticals International, Inc., Papa Joseph C had purchased shares worth of $4,944,960 in a transaction dated on June 10, 2016. A total of 202,000 shares were purchased at a price of $24.48 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Valeant Pharmaceuticals International (NYSE:VRX) witnessed a decline in the market cap on Friday as its shares dropped 1.69% or 0.38 points. After the session commenced at $22.42, the stock reached the higher end at $22.63 while it hit a low of $21.955. With the volume soaring to 22,955,510 shares, the last trade was called at $22.04. The company has a 52-week high of $263.81. The company has a market cap of $7,560 million and there are 343,030,280 shares in outstanding. The 52-week low of the share price is $21.955.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.